Search

Shining a Light on Blood Cancer

EHA Launches Digital Campaign

In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.

Read more

Meeting report | HOPE ASIA 2019 Kolkata

The first edition of the Highlights of Past EHA (HOPE) in Asia was held in Kolkata, India and was a great success.

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

Join EHA and SIE and receive up to €50 discount on your EHA membership

We are pleased to inform you that EHA and the Società Italiana di Ematologia (SIE) have joined forces and are offering you the possibility of an EHA-SIE Joint Membership.

Read more

Patient Advocacy Committee

Current committee members
Derek Elston, United Kingdom (Chair)
Samantha Nier (Switzerland) (Vice-chair)
Members representing a Patient Advocacy Organization

Organization
Member

Acute Leukaemia Advocates Network (ALAN)

Samantha Nier

CCI Europe

Anita Kienesberger

CLL Advocates Network (CLLAN)

Pierre Aumont

CML Advocates Network

Jan Geissler

European Federation of Associations of Patients with Haemochromatosis (EFAPH)

Dag Erling Stavik

European Haemophilia…

Read more

Abstract Submission & Travel Grant Application

Late Poster Submission is now closed.

Read more

EHA mapping of adolescent and young adult (AYA) hematology patient care

EHA has launched a major consultation to understand patient care for Adolescents and Young Adults (AYA) with hematological diagnoses across Europe.

Read more

EHA Statement on COVID-19

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.

Read more